Cisplatin-induced renal effects and thromboxane A2 receptor blockade.
The aim of this study was to evaluate the renal protective effect of linotroban, a thromboxane A2 receptor antagonist, in 25 patients with malignant tumours scheduled for cisplatin therapy. Cisplatin was administered 1 h after the start of a 24-h continuous infusion of linotroban or placebo. Glomerular filtration rate and effective renal plasma flow were measured. Infusions of cisplatin decreased glomerular filtration rate by 17 +/- 25 mL min-1 (P = 0.049 vs. baseline) and effective renal plasma flow by 94 +/- 150 mL min-1 (P = 0.049 vs. baseline) in the placebo group. In the linotroban group a decrease in glomerular filtration rate by 11 +/- 18 mL min-1 (P = 0.050 vs. baseline) and in effective renal plasma flow by 26 +/- 63 mL min-1 (P = 0.2 vs. baseline) was noted. However, no difference was noted between groups in response to treatment. Our findings indicate that linotroban may not be useful for prevention of cisplatin's acute nephrotoxic effects.
Dorner
G T
GT
Department of Clinical Pharmacology, Vienna University Hospital, Austria.
Pehamberger
H
H
Kornek
G
G
Steger
G
G
Müller
M
M
Wolzt
M
M
Kletter
K
K
James
P
P
Breiteneder
H
H
Eichler
H G
HG
Blöchl-Daum
B
B
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002945:Cisplatin / Q000009:adverse effects*; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006801:Humans; D007668:Kidney / Q000187:drug effects*; D008875:Middle Aged; D017482:Receptors, Thromboxane / Q000037:antagonists & inhibitors* / Q000502:physiology; D012079:Renal Circulation / Q000187:drug effects
D000970:Antineoplastic Agents; D017482:Receptors, Thromboxane; D002945:Cisplatin